Establishment of human hemotopoietic cell lines
Award last edited on: 2/25/02

Sponsored Program
Awarding Agency
Total Award Amount
Award Phase
Solicitation Topic Code

Principal Investigator
Robert I Kamen

Company Information

Genetics Institute Inc (AKA: GI)

87 Cambridge Park Drive
Cambridge, MA 02140
   (617) 876-1170
Location: Multiple
Congr. District: 07
County: Middlesex

Phase I

Contract Number: 1R43GM036250-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
Phase I Amount
The objective of the project is to establish human hematopoietic progenitor growth factordependent cell lines in culture. To accomplish this, researchers will first design and construct retroviral vectors that can infect and express cloned genes in the appropriate cell types. These would carry both a selectable marker gene and an oncogene. Second, researchers will establish murine cell lines producing the engineered retroviruses and develop assays to enable them to obtain reproducibly high virus titres and monitor expression of the oncogene(s) used.Researchers will then infect enriched populations of human hematopoletic progenitor cells and culture these in the presence (or absence) of defined growth/differentiation factors or conditioned media from human T-cell lines known to produce lymphokines. Finally, researchers will isolate individual cell lines from the infected cells and screen these for growth factor dependence/ independence. Such cell lines would be invaluable in the isolation, characterization, and functional optimization of these, and other, biological response modifiers and their specific cell surface receptors. In addition, they would be extremely useful as research tools to study hematopoiesis and could become valuable in drug screening programs to assess agents aimed at proliferative disorders of the hematopoietic system and to measure potential side effects of other chemotherapeutic agents.National Institute of General Medical Sciences (NIGMS)

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
Phase II Amount